Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;50(6):1409-1423.
doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4.

Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections

Sisi Zhen #  1 , Hui Wang #  1   2 , Sizhou Feng  3
Affiliations
Review

Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections

Sisi Zhen et al. Infection. 2022 Dec.

Abstract

Purpose: Multidrug-resistant Gram-negative bacteria (MDR-GNB) have become a major global public health threat. Ceftazidime-avibactam (CAZ-AVI) is a newer combination of β-lactam/β-lactamase inhibitor, with activity against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). The aim of this review is to describe the recent real-world experience of CAZ-AVI for the infections due to MDR-GNB.

Methods: We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. Reference lists were reviewed and synthesized for narrative review.

Results: MDRGNB infections are associated with higher mortality significantly comparing to drug-susceptible bacterial infections. Fortunately, CAZ-AVI shows significant benefits for infections due to KPC or OXA-48 CRE, comparing to colistin, carbapenem, aminoglycoside and other older agents, even in those with immunocompromised status. The efficacy of CAZ-AVI varies in different infection sites due to CRE, which is lower in pneumonia. Early use is associated with improved clinical outcomes. Noteworthy, when adopted as salvage therapy, CAZ-AVI is still superior to other GNB active antibiotics. CAZ-AVI plus aztreonam is recommended as the first line of MBL-CRE infections. However, for infections caused by KPC- and OXA-48-producing isolates, further investigations are needed to demonstrate the benefit of combination therapy. Besides CRE, CAZ-AVI is also active to MDR-PA. However, the development of resistance in CRE and MDR-PA against CAZ-AVI is alarming, and more investigations and studies are needed to prevent, diagnose, and treat infections due to CAZ-AVI-resistant pathogens.

Conclusions: CAZ-AVI appears to be a valuable therapeutic option in MDR-GNB infections. Using CAZ-AVI appropriately to improve efficacy and decrease the emergence of resistance is important.

Keywords: Carbapenem-resistant Enterobacterales; Ceftazidime–avibactam; Multidrug-resistant Gram-negative bacteria; Multidrug-resistant Pseudomonas aeruginosa.

PubMed Disclaimer

References

    1. Doi Y, Iovleva A, Bonomo R. The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world. J Travel Med. 2017;24:S44-S51. https://doi.org/10.1093/jtm/taw102 .
    1. Grundmann H, Glasner C, Albiger B, Aanensen D, Tomlinson C, Andrasević A, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63. https://doi.org/10.1016/s1473-3099(16)30257-2 . - DOI - PubMed
    1. Shortridge D, Gales A, Streit J, Huband M, Tsakris A, Jones R. Pseudomonas aeruginosageographic and temporal patterns of antimicrobial resistance in over 20 years from the SENTRY antimicrobial surveillance program, 1997–2016. Open Forum Infect Dis. 2019;6:S63–8. https://doi.org/10.1093/ofid/ofy343 . - DOI - PMC - PubMed
    1. Eichenberger E, Thaden J. Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. Antibiotics (Basel, Switzerland). 2019;8(2). https://doi.org/10.3390/antibiotics8020037 .
    1. Weiner L, Webb A, Limbago B, Dudeck M, Patel J, Kallen A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37:1288–301. https://doi.org/10.1017/ice.2016.174 . - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources